By the Top Tier Newswire AI Desk · August 3, 2026 at 9:50 AM ET · reviewed against 2 wire stories
CAREDX INC (CDNA) is up +9.59% in the latest session. Our newswire has captured 2 stories on CDNA across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why CDNA stock is up today
CareDx Inc (CDNA) rose 9.59% to $47.90 in intraday trading on August 3, 2026, driven by a combination of strategic leadership developments and strong earnings performance. The stock opened with a 0.7% gap up from the previous close and reached a session high of $48.18. The move follows the company’s announcement of a significant executive appointment and a recent acceleration of its financial guidance.
What Happened
CareDx announced the appointment of James McNally as Executive Advisor and the granting of 15,822 restricted stock units to him. The RSUs will vest in two equal tranches through 2027, signaling a strategic focus on leadership expansion and long-term growth. This development, combined with the company’s recent earnings beat and raised full-year sales guidance, has generated optimism among investors. The stock also benefited from a strong Q2 performance, including adjusted earnings of $0.37 per share and revenue of $131.948 million, both exceeding estimates. HC Wainwright & Co. reiterated a Neutral rating on the stock with a $46 price target, providing further context for the market reaction.
What The Data Shows
The stock opened at $44.02 and traded as low as $43.79 before surging to $48.18. Volume in the session reached 0.3 million shares, which is 0.4 times the 3-month average. The stock’s 52-week range is $11.26 to $45.00, and it has a market cap of $2.3 billion. Recent insider transactions include several sales by executives and directors, with a total of $8.2 million in sales reported over the past 90 days. Despite this, the stock’s fundamentals remain strong, with a P/E ratio of 20.6, revenue growth of 34.4% trailing twelve months, and a net margin of 24.2%.
What To Watch
Investors should monitor CareDx’s upcoming earnings report for further confirmation of its momentum. The company’s recent guidance and leadership moves suggest a continued focus on growth and operational strength.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CDNA · Aug 3 session (5-min) · +9.81% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 2 stories · 60/100 bullish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
7d agoMarketChameleonBULLISH 56General
CareDx Grants Nearly 16,000 RSUs to Executive Advisor as Part of Strategic Leadership Expansion
August 3, 2026
CareDx has granted 15,822 restricted stock units to its newly appointed Executive Advisor, James McNally, highlighting a leadership-focused growth move. The RSUs will vest in two equal tranches through 2027 and were approved under inducement provisions per Nasdaq requirements.
9d agoYahoo FinanceBULLISH 63General
Why CareDx Stock Jumped Today
The diagnostics leader is accelerating the trend toward precision medicine.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →